IQVIA Holdings Inc. $IQV Shares Bought by Capital World Investors

Capital World Investors raised its stake in IQVIA Holdings Inc. (NYSE:IQV) by 0.6% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 594,744 shares of the medical research company’s stock after buying an additional 3,480 shares during the period. Capital World Investors owned approximately 0.35% of IQVIA worth $134,061,000 at the end of the most recent reporting period.

A number of other hedge funds also recently added to or reduced their stakes in IQV. Ameliora Wealth Management Ltd. purchased a new position in IQVIA in the fourth quarter valued at about $25,000. International Assets Investment Management LLC purchased a new position in IQVIA in the fourth quarter valued at about $27,000. Measured Wealth Private Client Group LLC purchased a new position in IQVIA in the third quarter valued at about $30,000. Activest Wealth Management increased its holdings in IQVIA by 590.0% in the fourth quarter. Activest Wealth Management now owns 138 shares of the medical research company’s stock valued at $31,000 after buying an additional 118 shares in the last quarter. Finally, Atlantic Union Bankshares Corp purchased a new position in IQVIA in the third quarter valued at about $36,000. 89.62% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of brokerages have issued reports on IQV. Evercore reaffirmed an “outperform” rating and issued a $185.00 target price on shares of IQVIA in a report on Wednesday, April 8th. Mizuho set a $215.00 target price on shares of IQVIA in a report on Monday, February 23rd. HSBC set a $210.00 target price on shares of IQVIA in a report on Wednesday, June 3rd. Royal Bank Of Canada began coverage on shares of IQVIA in a research note on Tuesday, March 3rd. They set an “outperform” rating and a $221.00 price objective for the company. Finally, TD Cowen raised shares of IQVIA from a “hold” rating to a “buy” rating and raised their price objective for the stock from $174.00 to $213.00 in a research note on Monday, March 9th. Two research analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and two have assigned a Hold rating to the company. According to MarketBeat.com, IQVIA has an average rating of “Buy” and an average price target of $224.13.

IQVIA Trading Up 0.1%

Shares of IQV opened at $183.64 on Tuesday. The company has a debt-to-equity ratio of 2.20, a current ratio of 0.75 and a quick ratio of 0.75. The firm has a 50 day simple moving average of $172.42 and a 200-day simple moving average of $194.55. IQVIA Holdings Inc. has a 1-year low of $151.58 and a 1-year high of $247.04. The stock has a market cap of $30.65 billion, a price-to-earnings ratio of 22.76, a price-to-earnings-growth ratio of 1.57 and a beta of 1.21.

IQVIA (NYSE:IQV) last released its earnings results on Tuesday, May 5th. The medical research company reported $2.90 EPS for the quarter, topping the consensus estimate of $2.83 by $0.07. The firm had revenue of $4.15 billion during the quarter, compared to analysts’ expectations of $4.10 billion. IQVIA had a net margin of 8.33% and a return on equity of 30.50%. IQVIA’s revenue for the quarter was up 8.4% on a year-over-year basis. During the same period in the previous year, the company earned $2.70 EPS. IQVIA has set its FY 2026 guidance at 12.650-12.950 EPS. Equities analysts forecast that IQVIA Holdings Inc. will post 11.6 EPS for the current fiscal year.

IQVIA announced that its board has approved a stock buyback program on Thursday, May 7th that permits the company to repurchase $2.00 billion in shares. This repurchase authorization permits the medical research company to repurchase up to 6.8% of its shares through open market purchases. Shares repurchase programs are often a sign that the company’s board believes its shares are undervalued.

IQVIA Company Profile

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.